Objective To evaluate the efficacy and safety of the omadacycline-based therapies in patients with community-acquired pneumonia (CAP).Methods The clinical data of CAP patients treated with omadacycline (±β-lactam/β-lactamase inhibitor) in the First Affiliated Hospital of Nanchang University from January to May 2023 were reviewed and analyzed.The patients were assigned to omadacycline alone or omadacycline plus β-lactam/β-lactamase inhibitor treatment group.The clinical efficacy,microbiological efficacy,and drug-related adverse events were summarized and compared between groups.Results A total of 135 adult patients with CAP were enrolled,including 23 (17.04％) patients with chronic liver disease,25 (18.52％) patients with chronic kidney disease,and 64 (47.41％) patients treated with omadacycline alone.The overall clinical efficacy rate was 81.48％ (110/135),specifically 79.69％ (51/64) in the patients treated with omadacycline alone and 83.10％ (59/71) in the patients treated with omadacycline plus β-lactam/β-lactamase inhibitor.The clinical efficacy rate was 86.36％ (38/44) in the patients treated in the general ward.Overall,21 cases of drug-related adverse events (mainly nausea) were reported in 15 patients,all of which were mild to moderate.Conclusions Omadacycline has shown good therapeutic effect in treatment of CAP in Chinese adults,especially for the patients treated in general ward.Most of the adverse events of omadacycline were mild to moderate and tolerable.
维普
万方数据
